search for




 

Status of Usage of Anti-vascular Endothelial Growth Factor in Age-related Macular Degeneration
연령관련황반변성환자에서 항혈관내피성장인자의 국내 사용 현황
JKOS 2019 Aug;60(8):758-64
Published online August 15, 2019;  https://doi.org/10.3341/jkos.2019.60.8.758
Copyright © 2019 The Korean Ophthalmological Society.
PDF Download Count: 63 / View Count: 66

Songhee Cho, MS1, Sang Jin Shin, PhD1, Jae Kyung Suh, PhD1, Hajin Tchoe, MS1, Min Joo Kang, MS1, Jangmi Yang, MS1, Donghyun Jee, MD, PhD, MPH2
조송희1 · 신상진1 · 서재경1 · 최하진1 · 강민주1 · 양장미1 · 지동현2

Economic Evaluation Team, National Evidence Based Health Care Collaborating Agency1, Seoul, Korea
Department of Ophthalmology and Visual Science, St. Vincent Hospital, College of Medicine, The Catholic University of Korea2, Seoul, Korea
한국보건의료연구원 경제성평가연구단1, 가톨릭대학교 의과대학 성빈센트병원 안과 및 시과학교실2
Received May 3, 2018; Revised September 19, 2018; Accepted July 18, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Purpose: To evaluate the current use of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) in patients with age-related macular degeneration (AMD).
Methods: We analyzed the number and medical costs of patients with AMD diagnosed by the National Health Insurance Corporation (2007–2016). We also analyzed the number and medical costs of such patients who received anti-VEGF treatment, and analyzed the frequency, period of use, and average medical cost of anti-VEGF use in AMD patients. Finally, we evaluated the use of anti-VEGF injections for new AMD patients.
Results: The number of patients with AMD was 236,158 in 2009 and 537,528 in 2016, which represented a 2.3-fold increase over 8 years. Of these, the number of patients undergoing anti-VEGF therapy increased steadily from 9,961 in 2009 to 35,762 in 2016. The mean number of cycles of ranibizumab or aflibercept per patient was 4.87 ± 3.37, and the mean interval between treatments was 2.89 months. On average, 6.2 injections were performed in the first year of diagnosis, and the frequency of use decreased with time, with an average of 1.2 cycles after 4 years of diagnosis. Among all AMD patients in 2016, the total medical cost of those treated with anti-VEGF was 76.9 billion won, and the average medical cost per person was 2,162,145 won.
Conclusions: The use of two drugs, ranibizumab and aflibercept, as reflected in public health insurance claims, steadily increased over the study period. Notably, there was a tendency to substitute aflibercept for ranibizumab.
Keywords : Age-related macular degeneration, Intravitreal injection, Public health Korea, Ranibizumab

 

September 2019, 60 (9)